Psilocybin

Category: compound

A tryptamine psychedelic from psilocybin mushrooms being studied for neuroplasticity, end-of-life anxiety in cancer patients, and potential neuroprotective effects.

Mechanism Detail

Psilocybin is converted to psilocin, a 5-HT2A serotonin receptor agonist. This triggers a cascade of neuroplasticity: increased BDNF expression, dendritic spine growth, enhanced functional connectivity between brain regions, and dissolution of default mode network rigidity. Anti-inflammatory effects via TNF-α reduction have been observed.

Clinical Status

FDA breakthrough therapy designation for treatment-resistant depression. Phase II trials for end-of-life anxiety in cancer patients show significant lasting benefit. Schedule I in most jurisdictions. Oregon and Colorado have legalized supervised use.

Relevant Diseases

Relevant Therapies

Related Terms